drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (gene-modified CAR T cells)
drug_description
Autologous T cells engineered to express a chimeric antigen receptor targeting B7-H3 (CD276) and incorporating an inducible caspase-9 (iC9) safety switch; administered intraperitoneally to mediate T-cell cytotoxicity against B7-H3–positive ovarian cancer.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intraperitoneal
drug_mechanism_of_action
Autologous T cells are gene-modified to express a chimeric antigen receptor that binds B7-H3 (CD276) on tumor cells, triggering T-cell activation and cytotoxic killing via perforin/granzyme and cytokine release. The product includes an inducible caspase-9 (iC9) safety switch that can be activated (e.g., by rimiducid) to ablate the CAR-T cells in case of severe toxicity; administered intraperitoneally for B7-H3–positive ovarian cancer.
drug_name
iC9-CAR.B7-H3 autologous CAR-T cells
nct_id_drug_ref
NCT06305299